Treatment with GLP-1RAs was significantly associated with an improvement in eGFR slope in patients with diabetic nephropathy at high risk of disease progression.
Cohort (n=64)
No
Does intensive treatment improve eGFR slope in patients with diabetic nephropathy at high risk of disease progression?
Effect estimate: Coefficient -6.43 (95% CI -10.17 to -2.70)
p-value: p=<0.01
Objective: To explore the factors that contribute to the improvement in the annual change in the estimated glomerular filtration rate (eGFR slope) in patients with diabetic nephropathy at high risk of disease progression, particularly those with an eGFR of less than 30 mL/min/1.73 m2.
Kiku et al. (Thu,) conducted a cohort in Diabetic nephropathy (n=64). GLP-1RAs vs. Other treatments (ARBs, SGLT2i, or none) was evaluated on eGFR slope (annual change in eGFR) (Coefficient -6.43, 95% CI -10.17 to -2.70, p=<0.01). Treatment with GLP-1RAs was significantly associated with an improvement in eGFR slope in patients with diabetic nephropathy at high risk of disease progression.